From the Department of Pain Medicine, First Affiliated Hospital, China Medical University, Shenyang, China.
Department of Pain Medicine, People's Hospital affiliated to China Medical University, Shenyang, China.
Anesth Analg. 2022 Jul 1;135(1):178-190. doi: 10.1213/ANE.0000000000006016. Epub 2022 Apr 4.
Spinal cord stimulation (SCS) is an emerging, minimally invasive procedure used to treat patients with intractable chronic pain conditions. Although several signaling pathways have been proposed to account for SCS-mediated pain relief, the precise mechanisms remain poorly understood. Recent evidence reveals that injured sensory neuron-derived colony-stimulating factor 1 (CSF1) induces microglial activation in the spinal cord, contributing to the development of neuropathic pain (NP). Here, we tested the hypothesis that SCS relieves pain in a rat model of chronic constriction injury (CCI) by attenuating microglial activation via blocking CSF1 to the spinal cord.
Sprague-Dawley rats underwent sciatic nerve ligation to induce CCI and were implanted with an epidural SCS lead. SCS was delivered 6 hours per day for 5 days. Some rats received a once-daily intrathecal injection of CSF1 for 3 days during SCS.
Compared with naive rats, CCI rats had a marked decrease in the mechanical withdrawal threshold of the paw, along with increased microglial activation and augmented CSF1 levels in the spinal dorsal horn and dorsal root ganglion, as measured by immunofluorescence or Western blotting. SCS significantly increased the mechanical withdrawal threshold and attenuated microglial activation in the spinal dorsal horn in CCI rats, which were associated with reductions in CSF1 levels in the spinal dorsal horn and dorsal roots but not dorsal root ganglion. Moreover, intrathecal injection of CSF1 completely abolished SCS-induced changes in the mechanical withdrawal threshold and activation of microglia in the spinal dorsal horn in CCI rats.
SCS reduces microglial activation in the spinal cord and alleviates chronic NP, at least in part by inhibiting the release of CSF1 from the dorsal root ganglion ipsilateral to nerve injury.
脊髓刺激 (SCS) 是一种新兴的微创治疗方法,用于治疗难治性慢性疼痛疾病。尽管已经提出了几种信号通路来解释 SCS 介导的疼痛缓解,但确切的机制仍知之甚少。最近的证据表明,受伤的感觉神经元衍生的集落刺激因子 1 (CSF1) 诱导脊髓中的小胶质细胞活化,导致神经性疼痛 (NP) 的发展。在这里,我们通过阻断 CSF1 向脊髓的传递来测试 SCS 通过抑制小胶质细胞活化来缓解慢性缩窄性损伤 (CCI) 大鼠模型中疼痛的假说。
Sprague-Dawley 大鼠行坐骨神经结扎诱导 CCI,并植入硬膜外 SCS 导联。SCS 每天 6 小时,共 5 天。一些大鼠在 SCS 期间每天接受一次鞘内 CSF1 注射,共 3 天。
与正常大鼠相比,CCI 大鼠的足部机械退缩阈值明显降低,脊髓背角和背根神经节中的小胶质细胞活化增加,CSF1 水平升高,通过免疫荧光或 Western blot 测定。SCS 可显著增加 CCI 大鼠的机械退缩阈值,并减轻脊髓背角的小胶质细胞活化,这与脊髓背角和背根中的 CSF1 水平降低有关,但与背根神经节无关。此外,鞘内注射 CSF1 可完全消除 SCS 诱导的 CCI 大鼠脊髓背角机械退缩阈值和小胶质细胞活化的变化。
SCS 可减少脊髓中小胶质细胞的活化,并缓解慢性 NP,至少部分是通过抑制损伤侧背根神经节中 CSF1 的释放来实现的。